This CLEC9A–PD1 bispecific T‐cell engager (BiCE) promotes direct contact and reactivation of dysfunctional T cells within the TME, resulting in enhanced proliferation, effector function, and tumor clearance in preclinical models. This evidence concerns the gene CLEC9A and neoplasm.